ADU-1805
Cancer (unspecified)
PreclinicalActive
Key Facts
About Sairopa
Sairopa is a private, clinical-stage biotech company developing next-generation immunotherapies to address the limitations of current checkpoint inhibitors, which benefit only about 30% of cancer patients. Its core assets include ADU-1805 (anti-SIRPalpha) and ADU-1604 (anti-CTLA-4), acquired from Chinook Therapeutics and originally derived from the B-Select antibody platform used for Keytruda. The company is led by a small, experienced team with strong ties to Dutch life sciences investment firm Van Herk Investments and is currently advancing its lead candidate, ADU-1604, in Phase 1 clinical trials for advanced melanoma.
View full company profileTherapeutic Areas
Other Cancer (unspecified) Drugs
| Drug | Company | Phase |
|---|---|---|
| Allogeneic CAR-NK Platform Product | Simnova Biotherapeutics | Phase 1 |
| CAR-engineered NK cells | Glycostem | Pre-clinical |
| Lead Universal CAR-T Candidate | Allogenica | Pre-clinical |
| PSC-derived NK Cells | HebeCell | Pre-clinical |
| mRNA CAR-γδ-T Cell Platform | PhosphoGam | Pre-clinical |
| R-5780 | Rise Therapeutics | Phase 1 |
| Dendritic Cell-Based Cancer Vaccines | Celica Biomedical | Pre-clinical |
| PD-1/VEGF Program | OncoC4 | Not Disclosed |
| FC001 | FerroptoCure | Phase 1 |
| FC004 | FerroptoCure | Preclinical |
| Oncology Drug Delivery | Sporegen | Pre-clinical |